Insider Transactions in Q2 2023 at West Pharmaceutical Services Inc (WST)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 30
2023
|
Chad Winters VP, Chief Accounting Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
872
-37.59%
|
$295,608
$339.51 P/Share
|
|
May 30
2023
|
Chad Winters VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
872
+27.32%
|
$124,696
$143.43 P/Share
|
|
May 30
2023
|
Charles Witherspoon VP & Treasurer |
SELL
Open market or private sale
|
Direct |
1,000
-35.35%
|
$343,000
$343.05 P/Share
|
|
May 30
2023
|
Charles Witherspoon VP & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+26.12%
|
$102,000
$102.51 P/Share
|
|
May 09
2023
|
Eric Mark Green President, CEO and Board Chair |
SELL
Open market or private sale
|
Direct |
44,000
-5.45%
|
$15,972,000
$363.81 P/Share
|
|
May 09
2023
|
Eric Mark Green President, CEO and Board Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.87%
|
$2,850,000
$57.38 P/Share
|
|
May 05
2023
|
Chad Winters VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10
-0.69%
|
$3,680
$368.46 P/Share
|
|
May 01
2023
|
Silji Abraham SVP, Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,020
-36.82%
|
$2,927,300
$365.85 P/Share
|
|
May 01
2023
|
Silji Abraham SVP, Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,020
+39.61%
|
$689,720
$86.24 P/Share
|
|
May 01
2023
|
Thomas W Hofmann Director |
SELL
Open market or private sale
|
Direct |
1,212
-2.7%
|
$442,380
$365.57 P/Share
|
|
May 01
2023
|
Annette F Favorite Sr. VP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
13,012
-18.02%
|
$4,762,392
$366.46 P/Share
|
|
May 01
2023
|
Annette F Favorite Sr. VP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,012
+31.81%
|
$767,708
$59.64 P/Share
|
|
Apr 25
2023
|
Thomas W Hofmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+1.36%
|
-
|
|
Apr 25
2023
|
Stephen H Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+36.54%
|
-
|
|
Apr 25
2023
|
Mark A Buthman Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+1.47%
|
-
|
|
Apr 25
2023
|
Molly Joseph Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+33.05%
|
-
|
|
Apr 25
2023
|
Goldman Myla Lai Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+3.35%
|
-
|
|
Apr 25
2023
|
Paolo Pucci Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+6.21%
|
-
|
|
Apr 25
2023
|
Robert F Friel Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+16.82%
|
-
|
|
Apr 25
2023
|
Deborah L Keller Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+6.39%
|
-
|
|
Apr 25
2023
|
Douglas A Michels Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+1.4%
|
-
|
|
Apr 25
2023
|
William F Feehery Director |
BUY
Grant, award, or other acquisition
|
Direct |
616
+2.03%
|
-
|